The research program in Hematopoietic Cell Transplantation and Immune Reconstitution (Program 08) focuses on elucidating basic biological principles of hematopoietic cell transplantation (HCT) and furthering the treatment of patients with life-threatening hematologic malignancies. The major theme of the Program is the discovery of immunology and stem cell biology principles that can be translated into innovative HCT based therapies. Our goals are: ? To gain fundamental insights into the cellular basis of hematopoietic stem and progenitor cell engraftment. ? To explore the basic biology of graft-versus-host disease (GVHD) and graft-versus-tumor (GVT) reactions in the context of transplantation. ? To develop strategies to improve immune reconstitution. ? To translate promising concepts developed in pre-clinical studies to the clinic. Using a highly interactive group of investigators with a rich array of animal models incorporating the latest techniques of cell biology, imaging, genetics and array technologies we will explore in animal models and in patients the biological principles that govern these immune-based reactions and develop strategies to improve outcomes for our patients. These concepts could also have an impact on a variety of other clinical situations, such as for the treatment of autoimmune disorders and induction of solid organ transplantation tolerance. Using the principles of translational science whereby model systems are developed in the laboratory and concepts are tested in the clinic in a bi-directional fashion, analyzing patients'samples will allow us to test important concepts of HCT and follow critical leads established in research laboratories to the treatment of patients with hematologic disorders.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA124435-07
Application #
8475450
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
7
Fiscal Year
2013
Total Cost
$14,100
Indirect Cost
$4
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Pollom, Erqi L; Fujimoto, Dylann K; Han, Summer S et al. (2018) Newly diagnosed glioblastoma: adverse socioeconomic factors correlate with delay in radiotherapy initiation and worse overall survival. J Radiat Res 59:i11-i18
Nørgaard, Caroline Holm; Jakobsen, Lasse Hjort; Gentles, Andrew J et al. (2018) Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study. PLoS One 13:e0193249
Im, Hogune; Rao, Varsha; Sridhar, Kunju et al. (2018) Distinct transcriptomic and exomic abnormalities within myelodysplastic syndrome marrow cells. Leuk Lymphoma 59:2952-2962
Huang, Min; Zhu, Li; Garcia, Jacqueline S et al. (2018) Brd4 regulates the expression of essential autophagy genes and Keap1 in AML cells. Oncotarget 9:11665-11676
Chiou, Shin-Heng; Dorsch, Madeleine; Kusch, Eva et al. (2018) Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance. Sci Rep 8:14008
Breslow, David K; Hoogendoorn, Sascha; Kopp, Adam R et al. (2018) A CRISPR-based screen for Hedgehog signaling provides insights into ciliary function and ciliopathies. Nat Genet 50:460-471
Chu, Lisa W; Till, Cathee; Yang, Baiyu et al. (2018) Circadian genes and risk of prostate cancer in the prostate cancer prevention trial. Mol Carcinog 57:462-466
Patel, Manali I; Sundaram, Vandana; Desai, Manisha et al. (2018) Effect of a Lay Health Worker Intervention on Goals-of-Care Documentation and on Health Care Use, Costs, and Satisfaction Among Patients With Cancer: A Randomized Clinical Trial. JAMA Oncol 4:1359-1366
Trieu, Vanessa; Pinto, Harlan; Riess, Jonathan W et al. (2018) Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck. Oncologist 23:764-e86
Kuonen, François; Surbeck, Isabelle; Sarin, Kavita Y et al. (2018) TGF?, Fibronectin and Integrin ?5?1 Promote Invasion in Basal Cell Carcinoma. J Invest Dermatol 138:2432-2442

Showing the most recent 10 out of 322 publications